Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.61 |
| ▸ | CA9 | Q16790 | 1/20 | 0.61 |
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.48 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.48 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.48 |
| ▸ | PIM1 | P11309 | 1/20 | 0.48 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.47 |
| ▸ | PARP11 | Q9NR21 | 2/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.47 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.44 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | CASP2 | P42575 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17257956 | 0.77 | CA12 (0.42) | CA12CA9GSK3BDYRK1BLRRK2 | |
| SCHEMBL3296103 | 0.77 | PARP11 (0.64) | CA12CA9GSK3BPARP1HPGD | |
| SCHEMBL3918073 | 0.77 | CA12 (0.83) | CA12CA9GSK3BCLK4DYRK1B | |
| SCHEMBL442677 | 0.77 | GSK3B (0.57) | CA12CA9GSK3BCLK4DYRK1B | |
| SCHEMBL68595 | 0.76 | CA12 (0.45) | CA12CA9GSK3BDYRK1BLRRK2 | |
| SCHEMBL4818277 | 0.76 | CA12 (1.00) | CA12CA9GSK3BCLK4DYRK1B | |
| SCHEMBL14896 | 0.76 | CA12 (1.00) | CA12CA9GSK3BCLK4DYRK1B | |
| SCHEMBL29355184 | 0.76 | CA12 (1.00) | CA12CA9GSK3BCLK4DYRK1B | |
| SCHEMBL22313400 | 0.76 | PARP11 (0.62) | CA12CA9GSK3BPARP1HPGD | |
| SCHEMBL8213866 | 0.74 | CA12 (0.95) | CA12CA9GSK3BCLK4DYRK1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230175036-A1 | SELF-IMMOLATIVE PROBES FOR ENZYME ACTIVITY DETECTION | ENZO LIFE SCIENCES, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-11661621-B2 | Self-immolative probes for enzyme activity detection | ENZO LIFE SCIENCES, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-20180223328-A1 | COMPOUNDS AND METHODS FOR DETECTION OF ENZYMES THAT REMOVE FORMYL, SUCCINYL, METHYL SUCCINYL OR MYRISTOYL GROUPS FROM EPSILON-AMINO LYSINE MOIETIES | ENZO LIFE SCIENCES, INC. (US) | 2018-08-09 | — | — | US | disclosed |
| US-20180127456-A1 | MULTISIGNAL LABELING REAGENTS AND PROCESSES AND USES THEREFOR | Enzo Life Science, Inc., c/o Enzo Biochem, Inc. (US) | 2018-05-10 | — | — | US | disclosed |
| US-20180127455-A1 | MULTISIGNAL LABELING REAGENTS AND PROCESSES AND USES THEREFOR | Enzo Life Science, Inc., c/o Enzo Biochem, Inc. (US) | 2018-05-10 | — | — | US | disclosed |
| US-9963734-B2 | Compounds and methods for detection of enzymes that remove formyl, succinyl, methyl succinyl or myristoyl groups from epsilon-amino lysine moieties | ENZO LIFE SCIENCES, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-20170198333-A1 | COMPOUNDS AND METHODS FOR DETECTION OF ENZYMES THAT REMOVE FORMYL, SUCCINYL, METHYL SUCCINYL OR MYRISTOYL GROUPS FROM EPSILON-AMINO LYSINE MOIETIES | ENZO LIFE SCIENCES, INC. (US) | 2017-07-13 | — | — | US | disclosed |
| US-9664696-B1 | Compounds for determining the presence of hydrogen sulfide and methods of use | UNIVERSITY OF OREGON (US) | 2017-05-30 | — | — | US | disclosed |
| US-20170137863-A1 | Self-Immolative Probes for Enzyme Activity Detection | ENZO LIFE SCIENCES, INC., C/O ENZO BIOCHEM, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| US-9637773-B2 | Compounds and methods for detection of enzymes that remove formyl, succinyl, methyl succinyl or myristoyl groups from ε-amino lysine moieties | ENZO LIFE SCIENCES, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-20120122136-A1 | Self-immolative probes for enzyme activity detection | ENZO LIFE SCIENCES, INC., C/O ENZO BIOCHEM, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120040380-A1 | OPTICALLY-DETECTABLE ENZYME SUBSTRATES AND THEIR METHOD OF USE | Life Technologies Corporation (US) | 2012-02-16 | — | — | US | disclosed |
| US-20110318788-A1 | Multisignal labeling reagents and processes and uses therefor | ENZO LIFE SCIENCES, INC., C/O ENZO BIOCHEM, INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-8039506-B2 | Bicyclic lactam factor VIIa inhibitors useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-18 | — | — | US | disclosed |
| US-8039506-B2 | Bicyclic lactam factor VIIa inhibitors useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-18 | — | — | US | disclosed |
| US-7893071-B2 | Substituted phthalimide and isoquinoline derivatives; thalidomide analogs that lack the piperidine-2,6-dione moiety of thalidomide | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-02-22 | — | — | US | disclosed |
| US-20100041664-A1 | BICYCLIC LACTAM FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY | 2010-02-18 | — | — | US | disclosed |
| US-20100041664-A1 | BICYCLIC LACTAM FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY | 2010-02-18 | — | — | US | disclosed |
| WO-2005013914-A2 | HETEROARYLAMINOSULFONYLPHENYL DERIVATIVES FOR USE AS SODIUM OR CALCIUM CHANNEL BLOCKERS IN THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-02-17 | — | — | WO | disclosed |
| WO-1994027969-A1 | ISOQUINOLINETRIONE DERIVATIVES AS HERBICIDES | ZENECA LIMITED (GB) | 1994-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110318788-A1 | Multisignal labeling reagents and processes and uses therefor | PCNA, LIG4, LIG1 | CA12 4680/4885CA9 4884/4885GSK3B 2418/4885 |
| US-20100041664-A1 | BICYCLIC LACTAM FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | F7, F8, F9 | CA12 1594/4885CA9 656/4885GSK3B 388/4885 |
| US-20120122136-A1 | Self-immolative probes for enzyme activity detection | SORD, SI, IMMT | CA12 985/4885CA9 535/4885GSK3B 3005/4885 |
| US-20230175036-A1 | SELF-IMMOLATIVE PROBES FOR ENZYME ACTIVITY DETECTION | SORD, SI, IMMT | CA12 985/4885CA9 535/4885GSK3B 3005/4885 |
| US-11661621-B2 | Self-immolative probes for enzyme activity detection | MGAM, SI, ENGASE | CA12 637/4885CA9 499/4885GSK3B 3592/4885 |
| US-20180223328-A1 | COMPOUNDS AND METHODS FOR DETECTION OF ENZYMES THAT REMOVE FORMYL, SUCCINYL, METHYL SUCCINYL OR MYRISTOYL GROUPS FROM EPSILON-AMINO LYSINE MOIETIES | EMG1, SPR, SHMT1 | CA12 2706/4885CA9 2056/4885GSK3B 3065/4885 |
| US-20170137863-A1 | Self-Immolative Probes for Enzyme Activity Detection | MGAM, SI, ENGASE | CA12 637/4885CA9 499/4885GSK3B 3592/4885 |
| US-20180127455-A1 | MULTISIGNAL LABELING REAGENTS AND PROCESSES AND USES THEREFOR | PCNA, LIG4, LIG1 | CA12 4680/4885CA9 4884/4885GSK3B 2418/4885 |
| US-20170198333-A1 | COMPOUNDS AND METHODS FOR DETECTION OF ENZYMES THAT REMOVE FORMYL, SUCCINYL, METHYL SUCCINYL OR MYRISTOYL GROUPS FROM EPSILON-AMINO LYSINE MOIETIES | EMG1, SPR, SHMT1 | CA12 2706/4885CA9 2056/4885GSK3B 3065/4885 |
| US-20180127456-A1 | MULTISIGNAL LABELING REAGENTS AND PROCESSES AND USES THEREFOR | PCNA, LIG4, LIG1 | CA12 4680/4885CA9 4884/4885GSK3B 2418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.